PEOPLE - Changes at Interleukin Genetics:
This article was originally published in Clinica
Executive Summary
Interleukin Genetics, a Waltham, Massachusetts-based developer of gene-based inflammatory response risk-assessment and pharmacogenetic tests, has announced changes to its executive management team. Kenneth Kornman, founder, president and chief scientific officer, will also assume the role of CEO, replacing Philip Reilly, who continues as chairman of the board of directors; and Gregg Mayer, most recently the vice-president of strategic marketing and communications at EPIC Pharmaceuticals, has been appointed as chief business officer.